177 related articles for article (PubMed ID: 35395862)
1. Diagnostic value of thyroid imaging reporting and data system combined with BRAF
Wu L; Shu H; Chen W; Gao Y; Yuan Y; Li X; Lu W; Ye X; Deng H
Sci Rep; 2022 Apr; 12(1):5934. PubMed ID: 35395862
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
Lin Y; Luo YK; Li J; Ren XY; Wang HW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic values of BRAF(V600E) mutation analysis and Bethesda system for reporting thyroid cytopathology in thyroid nodules with TIRADS 4 and 5].
Han Y; Zhao BW; Li SY; Lyu JG; Shou JD; Xu HS; Lou HY; Xu LL; Gao L; Xu SX; Zhu J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):686-691. PubMed ID: 28910894
[No Abstract] [Full Text] [Related]
4. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
Zhang YZ; Xu T; Cui D; Li X; Yao Q; Gong HY; Liu XY; Chen HH; Jiang L; Ye XH; Zhang ZH; Shen MP; Duan Y; Yang T; Wu XH
Sci Rep; 2015 Nov; 5():16927. PubMed ID: 26597052
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules.
Sheng D; Yu X; Li H; Zhang M; Chen J
Medicine (Baltimore); 2021 Sep; 100(37):e27167. PubMed ID: 34664843
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Lu Y; Guo X; Yang M; Wang K; Cao G; Liu Y; Hou X; Chen L; Liang K
Sci Rep; 2023 Oct; 13(1):17129. PubMed ID: 37816788
[TBL] [Abstract][Full Text] [Related]
7. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
[TBL] [Abstract][Full Text] [Related]
8.
Wu Y; Xu T; Cao X; Zhao X; Deng H; Wang J; Li X; Yao Q; Ye X; Shen M; Wu X
Cancer Biol Med; 2019 Feb; 16(1):131-138. PubMed ID: 31119053
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
[TBL] [Abstract][Full Text] [Related]
10. The combination of BRAF
Li Q; Yang L; Lv J; Xu L; Zhang M; Li S
Endocrine; 2022 Dec; 78(3):507-516. PubMed ID: 36152114
[TBL] [Abstract][Full Text] [Related]
11. Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.
Seo JY; Kim EK; Kwak JY
Endocrine; 2014 Sep; 47(1):283-9. PubMed ID: 24452872
[TBL] [Abstract][Full Text] [Related]
12. Significance of FNAC, BRAF mutation, and intraoperative frozen section in surgical decision-making of thyroid nodules.
Zhu Z; Su C; Chen G; Wan F; Jin M; Duan X; Wang Y; Wang G
Diagn Cytopathol; 2023 Jul; 51(7):441-448. PubMed ID: 37042168
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
[TBL] [Abstract][Full Text] [Related]
14. BRAF
Chen H; Song A; Wang Y; He Y; Tong J; Di J; Li C; Zhou Z; Cai X; Zhong D; Da J
Cancer Med; 2022 Jan; 11(1):40-49. PubMed ID: 34851044
[TBL] [Abstract][Full Text] [Related]
15. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
16. Value of
Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Efficacy of Ultrasound, Cytology, and BRAF
Du J; Han R; Chen C; Ma X; Shen Y; Chen J; Li F
Front Oncol; 2021; 11():746776. PubMed ID: 35047385
[TBL] [Abstract][Full Text] [Related]
19. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
20. Incidence and predictive factors of inadequate fine-needle aspirates for BRAF(V600E) mutation analysis in thyroid nodules.
Lee KH; Kim HS; Han BK; Ko EY; Ki CS; Shin JH
AJR Am J Roentgenol; 2014 Feb; 202(2):391-6. PubMed ID: 24450682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
